Noticias de SNGX_US

Noticias del mercado

Últimas noticias sobre SNGX_US — 88 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: SNGX_US ✕ 88 resultados
28/04/2026 SNGX_US — Investing.com
Soligenix halts lymphoma drug trial after futility analysis By Investing.com
28/04/2026 SNGX_US — Investing.com UK
Soligenix halts lymphoma drug trial after futility analysis By Investing.com
28/04/2026 SNGX_US — MarketScreener
Soligenix Inc Announces Interim Results from Phase 3 Flash2 Trial Evaluating Hybryte in Treatment of Cutaneous T-Cell Lymphoma
28/04/2026 SNGX_US — TradingView
Soligenix halts Phase 3 FLASH2 HyBryte trial after futility; $5.9M cash, strategic options planned
28/04/2026 SNGX_US — PR Newswire
Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma
28/04/2026 SNGX_US — Benzinga
Why Is Soligenix Stock Sinking Tuesday?
28/04/2026 SNGX_US — TipRanks
Soligenix Halts FLASH2 Trial, Explores Strategic Alternatives
28/04/2026 SNGX_US — Stocktwits
SNGX Stock Slumps To Record Low After Lymphoma Trial Fails – All Eyes Now On Behçet’s Disease Treatment
28/04/2026 SNGX_US — Stock Titan
HyBryte FLASH2 failure leaves Soligenix (NASDAQ: SNGX) facing funding and pipeline risk
28/04/2026 SNGX_US — Investing.com
Soligenix halts lymphoma drug trial after futility analysis
25/04/2026 SNGX_US — Aktiellt ES ← EN
Soligenix recibe la designación de medicamento huérfano de la Comisión Europea para el SGX945 para el tratamiento de la enfermedad de Behçet (PR Newswire)

Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease (PR Newswire)

25/04/2026 SNGX_US — Aktiellt
Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency (PR Newswire)
21/04/2026 SNGX_US — Barchart.com
Soligenix (NASDAQ: SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation Approach
20/04/2026 SNGX_US — citybuzz -
Soligenix CEO Advocates for Patient-Centric Reformulation Strategy in Rare Disease Drug Development
20/04/2026 SNGX_US — Benzinga
Soligenix (NASDAQ: SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan Status
17/04/2026 SNGX_US — Barchart.com
Soligenix (NASDAQ: SNGX) Advances CTCL Research with Interim Analysis, Comparative Study Results
15/04/2026 SNGX_US — The Globe and Mail
Soligenix (NASDAQ: SNGX) Showcased for Smarter Path to Drug Development
14/04/2026 SNGX_US — MSN
Soligenix secures EU orphan drug designation for Behçet’s disease therapy
14/04/2026 SNGX_US — FinancialContent
MissionIRNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Showcased for Smarter Path to Drug Development
11/04/2026 SNGX_US — openPR.com
Mycosis Fungoides Treatment Market Surges to US$ 3.42 Billion

Página 2 de 5

keyboard_arrow_up